Walter Maksymowych, ACR 2020 – Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study
Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol.
The abstract entitled ‘Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study’ was presented at ACR Convergence 2020, 5-9 November.
- Could you give us a brief overview of the C-axSpAnd study and the aims of your recent analysis? (0:37)
- What predictors of response were identified? (2:11)
- What will be the impact of these findings on clinical practice? (5:34)
Disclosures: Walter Maksymowych is the Chief Medical Officer of CARE Arthritis Limited, has acted as a paid consultant/participated in advisory boards for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB; received research and/or educational grants from AbbVie, Novartis, Pfizer and UCB; and received speaker fees from AbbVie, Janssen, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1
BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings. The abstract ‘Bimekizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!